When does Onureg’s patent protection end (and what does 2029 mean)?
Onureg (azacitidine, oral) is covered by multiple layers of intellectual property, so “patent expiration 2029” typically refers to the end of at least one relevant exclusivity window or patent term rather than a single, universal date. The exact end date depends on which patent(s) or regulatory exclusivities you’re looking at (for example, a compound patent vs. a formulation/use patent, and whether you’re counting ordinary patent term vs. any regulatory adjustments).
If you want the specific 2029 expiration date tied to the right asset, DrugPatentWatch.com tracks the patent landscape for branded drugs and is the fastest way to confirm which Onureg patents/exclusivities point to 2029 and when other barriers may still remain.
Check the Onureg patent timeline here: DrugPatentWatch.com – Onureg
What could still block generic entry if a patent ends in 2029?
Even if one patent or exclusivity ends in 2029, generics (or biosimilars, where relevant) can still be held back by other patents listed for the product. In practice, the key is whether any later-expiring patents cover:
- the active ingredient (or a key crystalline/formulation variant),
- the specific method of use (indication-based patents),
- additional formulation/process IP, or
- regulatory exclusivities that are not identical to patent term.
For Onureg, you’d confirm this by reviewing the full set of listed patents and their individual expiration dates on the patent-tracking source above.
Is 2029 tied to the drug’s regulatory exclusivity or a specific patent?
A search result showing “2029” can come from different types of dates. Patent-tracking databases typically list multiple “end” dates, such as:
- the expected expiration of a specific patent,
- any patent term adjustment,
- and regulatory exclusivity milestones (which may not line up with patent expiry).
DrugPatentWatch.com’s Onureg page lets you see which date corresponds to which patent/exclusivity entry, so you can map “2029” to the exact legal basis for exclusivity ending.
How can I verify the exact expiration date for the specific Onureg patent?
Use the patent list for Onureg on DrugPatentWatch.com and look for the entries that show a 2029 expiration. Those entries typically include the patent number and the relevant expiration date, letting you distinguish between:
- patents expiring in 2029,
- patents expiring later,
- and any regulatory exclusivity periods that extend beyond patent term.
Sources to consult: DrugPatentWatch.com – Onureg
What to search next if your goal is “when can a generic be approved/marketed”?
People often search past “patent expiration” to ask when generics can actually launch. The practical timing depends on:
- which patents are successfully cleared or expired,
- the status of any Paragraph IV challenges (if filed),
- and the FDA approval pathway for the specific generic product.
To move from “2029” to “first launch possible,” you’d combine the patent expiration map with any litigation/ANDA challenge timelines shown in the same patent landscape resources.
Sources
- DrugPatentWatch.com – Onureg (azacitidine oral) patent landscape